Menu
Start Screening

Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

Mental Health Research Topics Medicine Anxiety

2 papers

Anxiety

Based on 52 papers

Research points to two clear groups of treatments for anxiety. First, ordinary approaches like exercise — especially walking and other regular physical activity — have strong, high-quality evidence showing medium-sized reductions in anxiety symptoms. These are proven in many randomized trials and reviews. Second, newer substance-assisted therapies (often called psychedelic‑assisted therapy) are promising. Small clinical trials and reviews show reductions in anxiety and related problems after carefully supervised doses of drugs such as psilocybin, MDMA, ketamine, and ayahuasca. However, these drug approaches are mostly early-stage or done in special research settings and need more, larger trials before they can become routine care. People thinking about or treating anxiety should know that drug‑assisted therapies are almost always given together with serious psychological support. How the drug is given, the preparation before it, and follow-up therapy matter a lot. There are also safety and equity issues to watch: some psychedelics can have rare lasting side effects, many studies are small, and people of color have been underrepresented in trials. For now, exercise has the clearest and broadest evidence. Other treatments are promising but still need more testing and careful medical oversight.

Key findings

  • Many high-quality reviews find regular physical activity reduces anxiety by a medium amount across many trials. 8792
  • Walking specifically lowers anxiety symptoms compared with doing nothing, based on 26 randomized trials pooled together. 8785
  • Clinical trials and reviews report that psychedelic-assisted therapies (drugs given with therapy) reduced anxiety symptoms in people diagnosed with anxiety disorders. 15068 15063 15056
  • For post‑traumatic stress disorder (a trauma-related anxiety condition), MDMA given with psychotherapy produced large benefits in several controlled trials. 15063
  • Psychedelic drugs appear to change the brain in ways that could help anxiety and mood problems. Lab and imaging studies report increased brain plasticity (the brain’s ability to form new connections) and changes in inflammation and brain networks after substances like psilocybin, DMT, and other psychedelics. 15132 15050 15091 15135
  • Ketamine produces fast antidepressant effects and has been tested as an alternative to electroconvulsive therapy; it has also been studied for anxiety-related conditions in some trials. 10149 10160 15068
  • Most studies of psilocybin and other classic psychedelics are small and done with close medical and psychological support, so experts say larger, well‑controlled trials are still needed before routine use. 15056 15078
  • How people are prepared and supported matters a lot: many guides and reviews agree that screening, setting expectations, building trust, and follow‑up therapy are core parts of substance‑assisted psychotherapy. 15065 15092 15063
  • People of color were underrepresented in many psychedelic-assisted psychotherapy studies, which limits how well the results apply to different ethnic groups. 15095
  • There are risks to be aware of: rare but long-lasting perceptual problems (called HPPD) and other psychological or physical side effects have been reported after hallucinogen use, so safety monitoring is important. 15048 15087

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l’humeur et de l’anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes

Raymond W. Lam, Sidney H. Kennedy, G. Camelia Adams, Anees Bahji, Serge Beaulieu, Venkat Bhat, et al.
The Canadian Journal of Psychiatry Summary & key facts 2024 240 citations

The CANMAT 2023 update gives doctors clear, up-to-date advice for treating adults with major depressive disorder. It puts evidence into a practical, clinician-friendly format. The update says treatment should be a team effort between patients and clinicians, be tailored to each person, and follow a planned, systematic process with regular…

Mental Health Research Topics Treatment of Major Depression Tryptophan and brain disorders

RETRACTED ARTICLE: ArticleNoteRapid and sustained antidepressant effects of intravenous ketamine in treatment-resistant major depressive disorder and suicidal ideation: a randomized clinical trial

Ahmad Zolghadriha, Afagh Anjomshoaa, Mohammad Jamshidi, Farnaz Taherkhani
BMC Psychiatry Summary & key facts 2024 20 citations

This paper reported a small, randomized trial of 64 people with treatment-resistant major depression who were given a single intravenous dose of ketamine or a saline placebo. The authors said depression and suicidal thoughts dropped quickly — within an hour — and that benefits lasted up to two months, but…

Mental Health Research Topics Treatment of Major Depression Tryptophan and brain disorders Ketamine
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.